Stock CYTK CYTOKINETICS, INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

All News Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Real-time Estimate Cboe BZX
Other stock markets
 10:13:56 2024-06-07 am EDT 		5-day change 1st Jan Change
51.2 USD -2.08% Intraday chart for Cytokinetics, Incorporated +5.31% -38.81%
Jun. 05 Sector Update: Health Care Stocks Advance Late Afternoon MT
Jun. 05 Sector Update: Health Care Stocks Rise Wednesday Afternoon MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Advance Late Afternoon
MT
Sector Update: Health Care Stocks Rise Wednesday Afternoon
MT
Sector Update: Health Care
MT
Cytokinetics Says Third Party Dropped Takeover Bid Despite Negotiations; Shares Rise
MT
Cytokinetics CEO Says Board Would Have Backed Actionable Buyout
DJ
Cytokinetics Incorporated : Regulation FD Presentation Form 8 K
PU
Cytokinetics Says Third Party Did Not Move Forward with Acquisition After Talks
CI
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
B. Riley Cuts Price Target on Cytokinetics to $92 From $122, Maintains Buy Rating
MT
Cytokinetics Insider Sold Shares Worth $635,978, According to a Recent SEC Filing
MT
Cytokinetics to Participate in June Investor Conferences
AQ
Truist Securities Lowers Price Target on Cytokinetics to $70 From $86, Maintains Buy Rating
MT
Cytokinetics Closes $500 Million Stock Offering
MT
Cytokinetics Announces Closing of Public Offering of Common Stock
AQ
JMP Securities Adjusts Cytokinetics Price Target to $78 From $106, Maintains Market Outperform Rating
MT
Cytokinetics, Incorporated announced that it has received $49.999992 million in funding from Royalty Pharma Development Funding, LLC
CI
Raymond James Adjusts Price Target on Cytokinetics to $70 From $92, Maintains Outperform Rating
MT
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday
MT
Nvidia Earnings Fuel Investor Optimism, Driving Premarket Gains for US Equity Futures
MT
Needham Adjusts Price Target on Cytokinetics to $72 From $108, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYTK Stock
  4. News Cytokinetics, Incorporated